Boston Scientific initiates clinical trial enrolment

Boston Scientific’s enrolment of its Promus Element Everolimus-Eluting Coronary Stent trial has begun, according to the company.

Named Platinum, the clinical programme will involve 1,728 patients at 160 sites around the world and will compare the product to the Promus Everolimus-Eluting Coronary Stent.

The organisation notes it aims to develop additional variations of the platform, including a bare-metal version and a paclitaxel-eluting Taxus design.

Commenting on the enrolment, Keith Dawkins, senior vice-president and associate chief medical officer for Boston Scientific, says the organisation is “excited” to begin the programme.

He continues: “The advanced Platinum Chromium Alloy and new balloon catheter offered in the Element Stent System represent significant improvements.”

Mr Dawkins notes Boston Scientific is the only company to offer a choice of drugs in its drug-eluting stent platform to interventional cardiologists.

In December, the company announced it had begun a Cabana post-market approval study of its Carotid Wallstent Monorail Endoprosthesis product.